Agoracom Blog

Novamind $ Weekly Roundup $ $MMED $ $ $CMPS $

Posted by AGORACOM-JC at 3:24 PM on Saturday, January 30th, 2021

A weekly summary of Novamind news and media

The Wall Street Reporter Interviewed Novamind’s CEO, Yaron Conforti

MULTIMEDIA January 27, 2021

Psychedelics and Eating Disorders

OPINION January 23, 2021

Novamind looks to scale mental health clinics and clinical sites with shift in psychedelics policies

MULTIMEDIA January 21, 2021

View all media

Novamind to Present at Canaccord Genuity conference: “New Paradigms & Treatment Approaches in Mental Health”

January 29, 2021

Novamind Reaches Major Milestones for Ketamine and Spravato™ Treatments

January 28, 2021

Novamind Announces Marketing Services Agreements

January 26, 2021

Novamind to Present at Inaugural KCSA Psychedelics Investor Conference

January 25, 2021

Former LifeLabs COO Joins Novamind Leadership Team

January 19, 2021

Novamind Expands Psychedelic Medicine Access in Utah

January 13, 2021

View all press releases

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit

Tags: , , , , , , , , ,

Comments are closed.